Now showing items 1-4 of 4

    • Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction : A prospective, observational, single-centre study 

      Adamski, Piotr; Sikora, Joanna; Laskowska, Ewa; Buszko, Katarzyna; Ostrowska, Małgorzata; Umińska, Julia M; Sikora, Adam; Skibińska, Natalia; Sobczak, Przemysław; Adamska, Urszula; Rość, Danuta; Kubica, Aldona; Paciorek, Przemysław; Marszałł, Michał P; Navarese, Eliano P; Gorog, Diana A; Kubica, Jacek (2017-10-12)
      BACKGROUND: Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation ...
    • Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial 

      Kubica, Jacek; Adamski, Piotr; Gorog, Diana A.; Kubica, Aldona; Jilma, Bernd; Budaj, Andrzej; Siller-Matula, Jolanta M.; Gurbel, Paul A.; Alexopoulos, Dimitrios; Badarienė, Jolita; Dąbrowski, Paweł; Dudek, Dariusz; Giannitsis, Evangelos; Horszczaruk, Grzegorz; Jaguszewski, Miłosz J.; James, Stefan; Jeong, Young Hoon; Kryjak, Michał; Niezgoda, Piotr; Ostrowska, Małgorzata; Patti, Giuseppe; Romanek, Janusz; Di Somma, Salvatore; Specchia, Giuseppe; Tantry, Udaya; Gąsior, Mariusz; Tycińska, Agnieszka; Wojakowski, Wojciech; Buszko, Katarzyna; Gil, Robert; Gruchała, Marcin; Kasprzak, Jarosław; Kleinrok, Andrzej; Legutko, Jacek; Lesiak, Maciej; Navarese, Eliano P. (2021-09-30)
    • Metabolism of ticagrelor in patients with acute coronary syndromes. 

      Adamski, Piotr; Buszko, Katarzyna; Sikora, Joanna; Niezgoda, Piotr; Barańska, Malwina; Ostrowska, Małgorzata; Paciorek, Przemysław; Navarese, Eliano P; Gorog, Diana; Kubica, Jacek (2018-09-06)
      Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation ...
    • A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study 

      Kubica, Jacek; Adamski, Piotr; Niezgoda, Piotr; Kubica, Aldona; Podhajski, Przemysław; Barańska, Malwina; Umińska, Julia M.; Pietrzykowski, Łukasz; Ostrowska, Małgorzata; Siller-Matula, Jolanta M.; Badarienė, Jolita; Bartuś, Stanisław; Budaj, Andrzej; Dobrzycki, Sławomir; Fidor, Łukasz; Gąsior, Mariusz; Gessek, Jacek; Gierlotka, Marek; Gil, Robert; Gorący, Jarosław; Grzelakowski, Paweł; Hajdukiewicz, Tomasz; Jaguszewski, Miłosz; Janion, Marianna; Kasprzak, Jarosław; Kern, Adam; Klecha, Artur; Kleinrok, Andrzej; Kochman, Wacław; Krakowiak, Bartosz; Legutko, Jacek; Lesiak, Maciej; Nosal, Marcin; Piotrowski, Grzegorz; Przybylski, Andrzej; Roleder, Tomasz; Skonieczny, Grzegorz; Sobieszek, Grzegorz; Tycińska, Agnieszka; Wojciechowski, Dariusz; Wojakowski, Wojciech; Wójcik, Jarosław; Zielińska, Marzenna; Żurakowski, Aleksander; Specchia, Giuseppe; Gorog, Diana A.; Navarese, Eliano P. (2021-06-02)
      The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet treatment ...